Director/PDMR Shareholding | RNS | Ticker

/News/RNS

Director/PDMR Shareholding

RNS Announcement

RNS Number : 7590M

GlaxoSmithKline PLC

17 October 2016

GlaxoSmithKline plc (the 'Company')

Transaction notification

Details of PDMR/person closely associated with them ('PCA')

Name

Ms E Walmsley

Position/status

CEO Designate

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	447.196

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Mr R G Connor

Position/status

President, Global Manufacturing & Supply

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 October 2016, on Ordinary Shares held in the Company's Deferred Investment Award Programme.

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Mr S A Hussain

Position/status

President, Global Pharmaceuticals

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	223.598

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Mr B McNamara

Position/status

CEO, GSK Consumer Healthcare

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

GlaxoSmithKline plc American Depositary Shares ('ADSs')

ISIN: US37733W1053

Nature of the transaction

Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's Deferred Investment Award Programme.

Price(s) and

volume(s)

Price(s)	Volume(s)
$42.0900	284.061

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Mr D S Redfern

Position/status

Chief Strategy Officer

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Ms C Thomas

Position/status

Senior Vice President, Human Resources

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	178.878

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

Details of PDMR/person closely associated with them ('PCA')

Name

Dr P J T Vallance

Position/status

President, Pharmaceuticals R&D

Initial notification/

amendment

Initial notification

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Name

GlaxoSmithKline plc

LEI

5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

Nature of the transaction

Price(s) and

volume(s)

Price(s)	Volume(s)
£16.9675	223.598

Aggregated information

Aggregated volume Price

n/a (single transaction)

Date of the transaction

2016-10-13

Place of the transaction

n/a

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHDDLFFQBFLFBQ

RNS metadata

Title: Director/PDMR Shareholding
Time: 19:28:21
Date: 17 Oct 2016
Category: Director/PDMR dealings
ID: 7590M